Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06474533 · ClinicalTrials.gov registry record
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
A clinical trial of Intracranial Neoplasm, sponsored by Thomas Hope.
- Recruiting
- Registry status
- 199
- Enrollment target
- 1
- Study location
NCT06474533: Recruiting study of Intracranial Neoplasm, sponsored by Thomas Hope.
NCT06474533 is a study of Intracranial Neoplasm that is actively recruiting participants, run by Thomas Hope. The registered enrollment target is 199 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06474533, a study of Intracranial Neoplasm, is actively recruiting participants, sponsored by Thomas Hope.
- RECRUITING
- Registry status
- 199 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
Primary Outcome
The maximum TBR (TBRmax) will be calculated by dividing the SUVmean of the 1.6 centimeter (cm) diameter circular region of interest (ROI) by the mean standardized uptake value (SUVmean) of background normal tissue.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography (PET)
- DRUG Fluorethyltyrosine (18-F)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2028-08-31 |
What NCT06474533 shows while recruiting
NCT06474533 is an observational study that tracks outcomes without assigning an intervention. The registered 199 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Intracranial Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Positron Emission Tomography (PET) is the first listed.
NCT06474533 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06474533 about?
NCT06474533 is a clinical study titled "Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm". This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
What is the current status of trial NCT06474533?
This trial is currently recruiting. The enrollment target is 199 participants. The study started on 2024-06-21. Estimated completion is 2028-08-31.
What conditions does trial NCT06474533 study?
This clinical trial studies the following conditions: Intracranial Neoplasm.
What interventions are being tested in trial NCT06474533?
The interventions under investigation include: Positron Emission Tomography (PET) (PROCEDURE), Fluorethyltyrosine (18-F) (DRUG).
Who is sponsoring clinical trial NCT06474533?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06474533 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intracranial Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04312126 · 199 participants
The Beneficial Effects of Naps on Motor Learning
- NCT04951622 · 199 participants · Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI